Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi KK

Division of Sanofi
www.sanofi-aventis.co.jp

Latest From Sanofi KK

2018 Completed Clinical Trials: Change Is The New Constant

Trialtrove’s annual review of clinical trials initiated by industry sponsors is a useful gauge of the diversity and innovative potential of biopharma’s investments in R&D. This year’s report reveals that, while there are patterns of consistency in many aspects of the trial landscape, changes are in the wind – particularly as companies outside the pharma top 20 now contribute more completed trials than any other type of sponsor.

Clinical Trials Market Intelligence

Sanofi Reaches For Post-Plavix Growth In Japan

While Sanofi’s Japanese pharma business is feeling the impact of generic competition to its former blockbuster top product, it is aiming to move back into growth through a string of planned launches over the next few years.

Japan Business Strategies

Biocon Confident As First Biosimilars Seen Hitting Europe In Early 2018

India’s leading biologics company Biocon has said it expects its first biosimilar products to be launched in the European market by early 2018 and is bullish on both its plans in the sector and earnings prospects after reporting quarterly net profit soared by a better than expected 52%.

India Biosimilars

Biocon Confident As First Biosimilars Seen Hitting Europe In Early 2018

India’s leading biologics company Biocon has said it expects its first biosimilar products to be launched in the European market by early 2018 and is bullish on both its plans in the sector and earnings prospects after reporting quarterly net profit soared by a better than expected 52%.

India Biosimilars
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Sanofi-Aventis Group Japan
  • Aventis Pharma Japan
  • Sanofi-Aventis KK
  • Sanofi-Aventis KK
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Sanofi
  • Senior Management
  • Jez Moulding, CEO
  • Contact Info
  • Sanofi KK
    Phone: (81) 3 6301 3000
    20-2, Nishishinjuku 3-chome
    Shinjuku-ku
    Tokyo, 163-1488
    Japan
Advertisement
Advertisement
UsernamePublicRestriction

Register